Health Canada Approves Cangene Hepatitis B Product
Posted on: Monday, 22 January 2007, 09:00 CST
Cangene has received approval from Health Canada for its HepaGam B hyperimmune product for the treatment of hepatitis B.
Health Canada has issued a Notice of Compliance with conditions which confers marketing approval to the drug in Canada, while requiring the company to continue with a confirmatory clinical study. The approved indication is for the prevention of hepatitis B recurrence following liver transplantation in adult patients who have low levels or no hepatitis B virus replication.
HepaGam B is the only intravenous product licensed in Canada for this indication. A Notice of Compliance with conditions is granted to provide patients who are suffering from serious, life-threatening or severely debilitating illnesses or conditions, accelerated access to promising new therapies.
HepaGam B was approved last year by the FDA for treatment following acute exposure to blood containing HBsAg, perinatal exposure of infants born to HBsAg-positive mothers, sexual exposure to HBsAG-positive persons and household exposure to persons with acute hepatitis B virus infection.
Source: Datamonitor
Related Articles
- Baird Balks at Environment Canada Plan to Exempt Firms in Bird Deaths
- France Challenges NATO to Agree on Conditions for Success in Afghanistan
- Merck Announces Voluntary Recall of Certain Lots of PEDVAXHIB(R) and COMVAX(R)
- GlaxoSmithKline Initiates Phase III Studies Hepatitis C Treatment
- Abbott Announces Approval of First Fully-Automated Blood Screening Test for Hepatitis C Antibodies
- FDA Approves Cangene's HepaGam B(TM) for a Second Indication; for Use in Hepatitis B-Positive Liver Transplant Recipients
- Some Potentially Fatal Conditions Affecting Moms-to-Be on the Rise: Study
- Thrush is One of Those Conditions That Just Affects the Female of the Species, Right? Wrong.
- Relating laboratory and outdoor exposure of coatings
 |
 |
User Comments (0)
RSS Feeds